non confidential presentation
play

NON-CONFIDENTIAL PRESENTATION November 2013 Founded February 2009, - PowerPoint PPT Presentation

Aug 28, 2023 •373 likes •473 views

NON-CONFIDENTIAL PRESENTATION November 2013 Founded February 2009, based in Vancouver, British Columbia Formerly AlCana Technologies Inc Highly experienced team developing lipid nanoparticle delivery systems Facilities for chemistry,

  1. NON-CONFIDENTIAL PRESENTATION November 2013

  2. Founded February 2009, based in Vancouver, British Columbia Formerly AlCana Technologies Inc Highly experienced team developing lipid nanoparticle delivery systems Facilities for chemistry, formulation and preclinical studies with access to additional resources at the University of British Columbia (UBC) Nov 2013 2

  3. Systemic lipid nanoparticles for intracellular delivery of molecular therapeutics – primarily nucleic acids Pharmaceutical applications: Protein replacement therapeutics (mRNA or plasmid delivery) Protein knockdown therapeutics (antisense) Nov 2013 3

  4. Multi-component carrier Small, uniform sized particles (~80 nm) Low surface charge in blood compartment Nov 2013 4

  5. Proof of Concept Studies using reporter mRNA Luciferase mRNA encapsulated in LNP – encapsulation efficiency >90%. In vivo administration (i.v.) to mice followed by: Quantitative luciferase expression determined ex vivo (Steady-Glo Luciferase assay kit: Promega) Live imaging (IVIS system) Nov 2013 5

  6. DOSE RESPONSIVE PROTEIN EXPRESSION Efficient mRNA delivery to liver. Luciferase expression proportional to mRNA dose (0.1-3.0 mg/kg) Nov 2013 6

  7. COMPARATIVE LNP POTENCY Acuitas LNP vs Phua et al. LNP 1 Luciferase expression in liver 4 hours after iv administration 1 Phua, Leong and Nair, J. Control Release, 166(3) 227-233, 2013 Nov 2013 7

  8. Focus on partnerships in protein replacement therapeutics Acuitas supports: Preclinical screening to select Lead Products Protection of Lead Products through new and existing IP rights Analytical, biophysical and preclinical characterization of Lead Products Transition from preclinical to clinical development Nov 2013 8

  9. Corporate Contact: Dr. Thomas Madden, President & CEO Phone: 604-880-6157 Email: tmadden@acuitastx.com Scientific Contact: Dr. Michael Hope, CSO Phone: 604-837-9239 Email: mhope@acuitastx.com Website: www.acuitastx.com LNP Technology developed under limited license from Tekmira Pharmaceuticals Corporation Nov 2013 9

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

the balance CONFIDENTIAL No stone to be unturned CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL

the balance CONFIDENTIAL No stone to be unturned CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL

CONFIDENTIAL HR Operational costs How to keep the balance CONFIDENTIAL No stone to be unturned CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL Stores incentive programs Immediate rewarding of results achievements and Quarterly payments for

463 views • 12 slides
Reebok CHECKLIGHT Overview MC10 CONFIDENTIAL 1 MC10 CONFIDENTIAL 2 MC10 CONFIDENTIAL 3 MC10

Reebok CHECKLIGHT Overview MC10 CONFIDENTIAL 1 MC10 CONFIDENTIAL 2 MC10 CONFIDENTIAL 3 MC10

Reebok CHECKLIGHT Overview MC10 CONFIDENTIAL 1 MC10 CONFIDENTIAL 2 MC10 CONFIDENTIAL 3 MC10 CONFIDENTIAL 4 REEBOK-MC10 C H E C K L I G H T Extra set of eyes for coaches, trainers and parents Comfortable and Conformal does Objective

318 views • 8 slides
Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2

Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2

Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2 Outline What is all this A.I. buzz about? What can it do? What will it change? What can you do? CONFIDENTIAL CONFIDENTIAL 3

649 views • 26 slides
Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2

Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2

Overview for Techdata Who, What & Why H2O Driverless AI? CONFIDENTIAL CONFIDENTIAL 2 Outline What is all this A.I. buzz about? What can it do? What will it change? What can you do? CONFIDENTIAL CONFIDENTIAL 3

759 views • 27 slides
P RIVATE AND C ONFIDENTIAL Confidential Confidential Material for the Board of Directors of

P RIVATE AND C ONFIDENTIAL Confidential Confidential Material for the Board of Directors of

P RESENTATION TO THE B OARD OF D IRECTORS OF Z UNICOM, I NC. January 12, 2012 P RIVATE AND C ONFIDENTIAL Confidential Confidential Material for the Board of Directors of Zunicom, Inc. THE ENCLOSED MATERIAL WAS COMPILED ON A CONFIDENTIAL BASIS

682 views • 36 slides
SWIM ATA UPI Payment Service Provider System ! 1 ! 2 Confidential CONFIDENTIAL SWIM ATA PSP

SWIM ATA UPI Payment Service Provider System ! 1 ! 2 Confidential CONFIDENTIAL SWIM ATA PSP

Confidential CONFIDENTIAL SWIM ATA UPI Payment Service Provider System ! 1 ! 2 Confidential CONFIDENTIAL SWIM ATA PSP System Integrates With UPI Critical to India UPI Payments Central to the Indian economy Unified Payment Interface

777 views • 13 slides
Introduction to Castlight Health Excerpts from a presentation to the Insurance Committee on

Introduction to Castlight Health Excerpts from a presentation to the Insurance Committee on

Introduction to Castlight Health Excerpts from a presentation to the Insurance Committee on February 19, 2014 confidential | page 1 CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL CONFIDENTIAL Castlight

539 views • 6 slides
INTERSECTION LINKUK CONFIDENTIAL 3 3 INTERSECTION LINKUK CONFIDENTIAL 4 Not drawn to scale

INTERSECTION LINKUK CONFIDENTIAL 3 3 INTERSECTION LINKUK CONFIDENTIAL 4 Not drawn to scale

INTERSECTION LINKUK CONFIDENTIAL 3 3 INTERSECTION LINKUK CONFIDENTIAL 4 Not drawn to scale INTERSECTION LINKUK CONFIDENTIAL 5 INTERSECTION LINKUK CONFIDENTIAL 6 ? 1993 1995 2005 2008 2015 2016+ # Dimension Comparisons: Link

639 views • 14 slides
SECURITY AND CUSTOMER EXPERIENCE IN SELF SERVICE A brief history NCR Confidential - Use

SECURITY AND CUSTOMER EXPERIENCE IN SELF SERVICE A brief history NCR Confidential - Use

SECURITY AND CUSTOMER EXPERIENCE IN SELF SERVICE A brief history NCR Confidential - Use and Disclose Solely Pursuant to Company Instructions NCR Confidential NCR Confidential friction Experience = + confusion NCR Confidential NCR

967 views • 60 slides
PACKER. TO BE OR NOT TO BE? 1 1 CONFIDENTIAL CONFIDENTIAL About me Devops lead with more

PACKER. TO BE OR NOT TO BE? 1 1 CONFIDENTIAL CONFIDENTIAL About me Devops lead with more

PACKER. TO BE OR NOT TO BE? 1 1 CONFIDENTIAL CONFIDENTIAL About me Devops lead with more than 8 years of experience in system administration which includes Media servers Load balancing technologies and cloud technologies-

588 views • 27 slides
Whats new with ? September 2016 Confidential +

Whats new with ? September 2016 Confidential +

Whats new with ? September 2016 Confidential + Proprietary Confidential + Proprietary Nice to meet you! Eileen Huang Google for Education Program Manager @eileenhuang | #GoogleEDU Confidential +

811 views • 65 slides
What You Should Know Proprietary and Confidential Proprietary and Confidential A New Medical

What You Should Know Proprietary and Confidential Proprietary and Confidential A New Medical

What You Should Know Proprietary and Confidential Proprietary and Confidential A New Medical Liability Crisis The medical liability situation worsened in the late 1990s Minimal reforms of 1995 failed Mandatory rate roll backs were not

933 views • 35 slides
Sunrise Electronics Inc. 11/4/2002 11/4/2002 1 1 1 1 CONFIDENTIAL CONFIDENTIAL

Sunrise Electronics Inc. 11/4/2002 11/4/2002 1 1 1 1 CONFIDENTIAL CONFIDENTIAL

Sunrise Electronics Inc. 11/4/2002 11/4/2002 1 1 1 1 CONFIDENTIAL CONFIDENTIAL Presentation Agenda Corporate Overview Product Capability Advanced Technology Question & Answer 11/4/2002 11/4/2002 2 2 2 2

604 views • 23 slides
Our Mission and Guiding Principles Privileged and Confidential Privileged and Confidential M

Our Mission and Guiding Principles Privileged and Confidential Privileged and Confidential M

Our Mission and Guiding Principles Privileged and Confidential Privileged and Confidential M ISSION & GROUP STRUCTURE To ensure that every individual and every enterprise has complete access to financial services N EW N EW I NITIATIVES I

153 views • 11 slides
SS Concordia | CONFIDENTIAL # Free Speech isnt Free, Unless you are a Bull |

SS Concordia | CONFIDENTIAL # Free Speech isnt Free, Unless you are a Bull |

SS Concordia | CONFIDENTIAL # Free Speech isnt Free, Unless you are a Bull | CONFIDENTIAL # Network Associates / McAfee Loading | CONFIDENTIAL # CONFIDENTIAL Valeant and Concordia (Poor Mans

1.03k views • 50 slides
LPCA Workshop CONFIDENTIAL This file contains information that is confidential to Azara

LPCA Workshop CONFIDENTIAL This file contains information that is confidential to Azara

November 13, 2018 LPCA Workshop CONFIDENTIAL This file contains information that is confidential to Azara Healthcare, LLC Do not view, copy, distribute, or disclose without prior consent. Introductions Meet Your Peers and Azara Staff

1.63k views • 144 slides
Interfacing Nanoparticles to Biology Kimberly Hamad-Schifferli Biological and Mechanical

Interfacing Nanoparticles to Biology Kimberly Hamad-Schifferli Biological and Mechanical

Interfacing Nanoparticles to Biology Kimberly Hamad-Schifferli Biological and Mechanical Engineering, MIT Understanding and Synthesis of nanoparticles with Nanoscale interfaces manipulation of particle unique properties with proteins and

206 views • 6 slides
2013 TzuChiU_Formosa Team Team Membe Members rs Hypnoseq. Hypnos Sequence Right before Us

2013 TzuChiU_Formosa Team Team Membe Members rs Hypnoseq. Hypnos Sequence Right before Us

2013 TzuChiU_Formosa Team Team Membe Members rs Hypnoseq. Hypnos Sequence Right before Us Right before Us Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness,

457 views • 43 slides
OLDER ADULTS WITH HIV: WHAT YOU NEED TO KNOW Panel Discussion: The War Against HIV/AIDS Rages On

OLDER ADULTS WITH HIV: WHAT YOU NEED TO KNOW Panel Discussion: The War Against HIV/AIDS Rages On

OLDER ADULTS WITH HIV: WHAT YOU NEED TO KNOW Panel Discussion: The War Against HIV/AIDS Rages On Building Successful Academic Partnerships to Achieve Health Equity Forum Atlanta Clinical and Translational Science Institute Community Engagement

247 views • 20 slides
HIV and development challenges for Africa Catherine Hankins, Associate Director &

HIV and development challenges for Africa Catherine Hankins, Associate Director &

HIV and development challenges for Africa Catherine Hankins, Associate Director & Chief Scientific Adviser to UNAIDS Session: Challenges of globalisation, regional integration and development of Africa 10 th Anniversary of the Centre

801 views • 35 slides
DNA Coated Gold Nanoshells for Laser Induced Antisense Drug Release in Cells Marcus Rosario

DNA Coated Gold Nanoshells for Laser Induced Antisense Drug Release in Cells Marcus Rosario

DNA Coated Gold Nanoshells for Laser Induced Antisense Drug Release in Cells Marcus Rosario Mentor Gary Braun Dr. Norbert Reich National Institutes of Health Ventura College Molecular Biology The Big Picture Research Goals Attach

351 views • 18 slides
W ave Life Sciences: Exon Skipping Approach for the Potential Treatment of DMD Little Steps

W ave Life Sciences: Exon Skipping Approach for the Potential Treatment of DMD Little Steps

W ave Life Sciences: Exon Skipping Approach for the Potential Treatment of DMD Little Steps Association DBMD Patient Conference June 6, 2018 1 Disclosures Dr. Dor is not an employee of Wave Life Sciences, consultant or otherwise

105 views • 7 slides
Pre-amplification critically analysed Jo Vandesompele professor, Ghent University co-founder and

Pre-amplification critically analysed Jo Vandesompele professor, Ghent University co-founder and

Pre-amplification critically analysed Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle Advanced Methods in RNA quantification (London, UK) May 21, 2009 outline introduction 450 miRNA pre-amplification

553 views • 51 slides
On the Submodularity of Influence in Social Networks Elchanan Mossel & Sebastien Roch

On the Submodularity of Influence in Social Networks Elchanan Mossel & Sebastien Roch

On the Submodularity of Influence in Social Networks Elchanan Mossel & Sebastien Roch STOC07 Speaker: Xinran He Xinranhe1990@gmail.com Social Network Social network as a graph Nodes represent individuals. Edges are social

611 views • 40 slides

More recommend